Therapeutically active triazoles and their use

Details Therapeutically active triazoles and their use Therapeutically active triazoles and their use

2007-09-18

2011-12-20

Badio, Barbara P (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C514S825000, C514S826000, C514S863000, C514S866000, C514S903000, C540S108000

Reexamination Certificate

active

08080540

ABSTRACT:
Estratrien-triazoles corresponding to formula (I) (shown below) which are useful in therapy, especially for the treatment and/or prevention or inhibition of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.

REFERENCES:
patent: 3347878 (1967-10-01), Boswell
patent: 3413321 (1968-11-01), Boswell, Jr.
patent: 5993856 (1999-11-01), Ragavan et al.
patent: 6416778 (2002-07-01), Ragavan et al.
patent: 6541463 (2003-04-01), Labrie et al.
patent: 6652874 (2003-11-01), Ragavan et al.
patent: 6903102 (2005-06-01), Guzi et al.
patent: 2003/0170292 (2003-09-01), Yong et al.
patent: 2006/0009434 (2006-01-01), Hillisch et al.
patent: 2006/0052461 (2006-03-01), Hillisch et al.
patent: 2006/0271710 (2006-11-01), Chang et al.
patent: 0 367 576 (1990-05-01), None
patent: 0 977 555 (1998-07-01), None
patent: 0902022 (2006-06-01), None
patent: WO 99/46279 (1999-09-01), None
patent: WO 00/07996 (2000-02-01), None
patent: WO 01/42181 (2001-06-01), None
patent: WO 02/26706 (2002-04-01), None
patent: WO 03/017973 (2003-03-01), None
patent: WO 03/022835 (2003-03-01), None
patent: WO 03/033487 (2003-04-01), None
patent: WO 03/101972 (2003-12-01), None
patent: WO 2004/046111 (2004-06-01), None
patent: WO 2004/060488 (2004-07-01), None
patent: WO 2004/080271 (2004-09-01), None
patent: WO 2004/085345 (2004-10-01), None
patent: WO 2004/085457 (2004-10-01), None
patent: WO 2004/110459 (2004-12-01), None
patent: WO 2005/032527 (2005-04-01), None
patent: WO 2005/047303 (2005-05-01), None
patent: WO 2005/084295 (2005-09-01), None
patent: WO 2006/003012 (2006-01-01), None
patent: WO 2006/003013 (2006-01-01), None
patent: WO 2006/027347 (2006-03-01), None
patent: WO 2006/032885 (2006-03-01), None
patent: WO 2006/063585 (2006-06-01), None
patent: WO2006/063615 (2006-06-01), None
patent: WO 2006/125800 (2006-11-01), None
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Vippagunta et al. (Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26).
Deluca et al., “Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases.” Molecular and Cellular Endocrinology, vol. 248, pp. 218-224, 2006.
“Lessons learned from marketed and investigational pro-drugs”, J.Med.Chem., 47, 2393-2404, 2004, Ettmayer et al.
Andersen, S.; (1995) “Molecular genetics of androgenic 17β-Hydroxysteroid Dehydrogenases”; J. Steroid Biochem. Molec. Biol., 55(5-6):533-534.
Andersen, J et al.; (2005) “Efficient One-Pot Synthesis of 1-Aryl 1,2,3-Triazoles from Aryl Halides and Terminal Alkynes in the Presence of Sodium Azide” Synlett, 2005, 19:2941.
Burow, Me et al.; “Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta”;J. Clin. Endocrinol. Metab. 86 (2001) (4), pp. 1750-1758.
Dong, Y et al. (1998) “17β-hydroxysteroid dehydrogenases in human bone cells”; J. Bone Min. Res., 13:1539-1546.
Einspanier, A. et al.; “Induction of endometriosis in the marmoset monkey (Callithrix jacchus)”; Mol Hum Reprod. May 2006;12(5):291-9. Epub Apr. 11, 2006.
Geissler WM et al. (1994) “Male pseudohermaphroditism caused by mutations of testicular 17beta-hydroxysteroid dehydrogenase 3.”; Nat Genet., 7:34-9.
Gruemmer, R. et al.; “Peritoneal endometriosis: validation of an in vivo model”;Hum. Reprod. 16 (2001) (8), pp. 1736-1743.
Husen, B. et al.; (2006) “Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme”; Mol Cell Endocrinol. Mar. 27, 2006;248(1-2):109-13. Epub Jan. 10, 2006.
Koffmann B et al. (1991) “Evidence for involvement of tyrosine in estradiol binding by rat uterus estrogen receptor.” J. Steroid. Biochem. Mol. Biol. 38(2):135-139.
Labaree et al. (2003] “Synthesis and Evaluation of B-, C- and D-ring substituted estradiol carboxylic acid esters as locally active estrogens” J. Med. Chem. 46:1886-1904.
Labrie F et al. (1997) “The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology.” Steroids, 62:148-58.
Labrie et al. (2000) “Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues” Trends Endocrinol Metab., 11:421-7.
Lawrence et al (2005) “Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.” J Med Chem. 48(8):2759-62.
Liu et al (1992) “Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography.” J Med Chem. 35(11):2113-29.
Medicinal Chemistry: Principles and Practice, 1994, ISBN 0-85186-494-5, Ed.: F. D. King, p. 215.
Oefelein, MG & Cornum, R (2000) “Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.” J Urol.; 164(Iss. 3, Pt. 1):726-9.
Pelletier & Poirier (1996) “Synthesis and evaluation of estradiol derivatives with 16α-(bromoalkylamide), 16α-(bromoalkyl) or 16α-(bromoalkynyl) side chain as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 without estrogenic activity” Bioorg Med Chem, 4(10):1617-1628.
Poirier et al. (1991) “Synthesis of 17β-estradiol derivatives with N-Butyl, N-methyl alkylamide side chain at position 15.” Tetrahedron, 47(37):7751-7766.
Poirier et al. (1996) “D-Ring alkylamine derivatives of estradiol: effect on ER-binding affinity and antiestrogenic activity” Bioorg Med Chem Lett 6(21):2537-2542.
Poirier et al. (1998) “A 6β-(Thiaheptanamide) Derivative of Estradiol as inhibitor of 17β-Hydroxysteroid Dehydrogenase Type 1”, J. Steroid Biochem. Molec. Biol., 64:83-90.
Poirier, D.; (2003) “Inhibitors of 17 beta-hydroxysteroid dehydrogenases” Curr Med Chem. 10:453-77.
Rostovtsev, VV. et al.; “A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective Ligation of Azides and Terminal Alkynes” Angew. Chem., 2002, 41(14), 2596-2599.
Sam et al. (1998) “C16 and C17 Derivatives of Estradiol as Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1: Chemical Synthesis and Structure-Activity Relationships”, Drug Design and Discovery, 15(3):157-180.
Stella, J; “Pro-drugs as therapeutics”, Expert Opin. Ther. Patents, 14(3), 277-280, 2004.
Suginome et al. (1989), J. Org. Chem, 54(25) 5945.
Tamaya et al. (1985) “Comparison of cellular levels of steroid receptors in uterine leiomyoma and myometrium.” Acta Obstet Gynecol Scand., 64:307-9.
Tremblay & Poirier (1998) “Overview of a Rational Approach to Design Type I 17β- Hydroxysteroid Dehydrogenase inhibitors Without Estrogenic Activity: Chemical Synthesis and Biological Evaluation”, J. Steroid Biochem. Molec. Biol., 66:179-191.
Chetrite and Pasqualini (2001) “The selective estrogen enzyme modulator (SEEM) in breast cancer” Journal of Steroid Biochemistry & Molecular Biology 76: 95-104.
Smith et al. (2001) “Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers” Exp. Opin. Ther. Patents 11(5): 789-824.
Blomquist et al. (2002) “Androgenic and estrogenic 17beta-hydroxysteroid dehydrogenase/17-ketosteroid reductase in human ovarian eipthelial tumors: evidence for the type 1, 2, and 5 isoforms” Journal of Steroid Biochemistry & Molecular Biology, 153: 453-464.
Zeitoun and Bulun (1999) ȁ

Affiliated with

Also associated with

Rating

Therapeutically active triazoles and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutically active triazoles and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutically active triazoles and their use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4297271